INTERVENTIONALUNKNOWNNCT04195269
Osteoarthritis of the Knee Pain Study Using CBD and THC in Rapidly Dissolvable Sublingual Tablet
This study is a prospective Phase 2, drug controlled, open-label study to evaluate the safety and efficacy of Pure Green sublingual tablets for the treatment of pain associated with osteoarthritis of the knee.
Locally preserved from ClinicalTrials.govOpen ClinicalTrials.gov↗last source update 2020-04-14
What this record can show
Protocol only - no registry results posted
This locally preserved record separates the registered protocol from source-reported registry results. Neither is a treatment recommendation.
Registry facts
Study at a glance
- Phase
- PHASE2
- Enrollment
- 30 (ESTIMATED)
- Start date
- 2020-04-20
- Sponsor
- Pure Green
- Design
- NA · SINGLE GROUP · TREATMENT
- Locations
- 1
- Results record
- Not present in registry snapshot
Osteoarthritis, KneePainCBDTHCCannabidiolTetrahydrocannabinolOsteoarthritisKneePain
Linked local records
Related local records
Local links use governed condition terms or exact source-reported intervention names. They are navigation candidates, not efficacy claims.
Conditions
No published condition report matched.
Cannabinoids and active compounds
No governed compound link was found.
Medicines
No exact medicine-name link was found.
Research network
Researchers and organizations
Interventions
What was registered
DRUGTest Article
10 mg CBD, 10 mg of THC, and a proprietary blend of terpenes.
Eligibility
Population and criteria
- Sex
- ALL
- Minimum age
- 21 Years
- Maximum age
- Not reported
- Healthy volunteers
- Not accepted
Inclusion criteria
- 1. Subject is at least 21 years of age; 2. Subject has a diagnosis of a pain related to osteoarthritis of the knee as determined by the subject's primary care physician or related health care provider. 3. Subject has a mean pain scale score of ≥ 4 recorded in the 7 days prior to enrollment. 4. If female, the subject is postmenopausal (\> 1 year), surgically sterile (\> 3 months), had a hysterectomy, or is currently using 2 effective forms of birth control. 5. Subject has not taken marijuana (cannabis) in any form, chemicals or extracts or foods or beverages or topical creams, lotions, gels, patches containing marijuana (cannabinoids, or and cannabis derivatives) including synthetic marijuana and/or CBD for at least 14 days prior to this study, and promises to not take marijuana (cannabis) in any form, chemicals or extracts or foods or beverages or topical creams, lotions, gels, patches containing marijuana (cannabinoids, or and cannabis derivatives) including synthetic marijuana and/or CBD while participating in this study. 6. Subject has not taken any pain medication, including NSAIDs, for at least 2 days before taking the first dose of study drug. 7. Subject is willing to provide his/her written informed consent to participate in the study as stated in the informed consent document. 8. Subject is willing to use an electronic diary to enter a pain scale score up to four times a day for 28 days.
Exclusion criteria
- 1. Subject is pregnant or lactating; 2. Subject has an allergy to cannabis, the Cannabaceae plant family (e.g., hemp, hops), palmitoylethanolamide, or terpenes; 3. Subject has a known allergy to active or inert ingredients of PG-OA-10:10-2020-B tablets; 4. Subject is taking a concomitant medication or treatment that would complicate use or interpretation of the study drug's effects (examples include: Cannabis or any cannabinoid products; Any drug or herbal product that influences the endocannabinoid system (ECS)); 5. Subject is taking marijuana (cannabis) in any form, chemicals or extracts or foods or beverages or topical creams, lotions, gels, patches containing marijuana (cannabinoids, or and cannabis derivatives) including synthetic marijuana and/or CBD for at least 14 days prior to this study, and does not promise that they will not take marijuana (cannabis) in any form, chemicals or extracts or foods or beverages or topical creams, lotions, gels, patches containing marijuana (cannabinoids, or and cannabis derivatives) including synthetic marijuana and/or CBD while participating in this study; 6. Subject is currently being treated with antibiotics for sinus, throat, or lung infections; 7. Subject has shortness of breath associated with allergies; 8. Subject has uncontrolled asthma; 9. Subject has a fever and/or productive cough; 10. Subject has unstable angina, uncontrolled hypertension; 11. Subject currently or has a history of congestive heart failure; 12. Subject has any other unstable medical condition; 13. Subject has a personal or family history of schizophrenia; 14. Subject has a personal history or currently has suicidal ideation or attempted suicide; 15. Subject has a major neurological disorder, such as dementia, Parkinson's disease, cognitive impairment, epilepsy, history of traumatic brain injury/head injury, and seizures. 16. Subject has taken pain medicine of any kind throughout the screening period, or has taken acetaminophen within 2 days of taking the first dose of study drug. 17. Subject has an allergy to, or has an intolerance to, acetaminophen. 18. Subject is currently taking any form of opioids. 19. Subject has a history of alcohol or substance abuse 20. Subject has clinically significant illness, including cardiovascular disorders. 21. Subject has any condition in which the investigator believes will confound the data of the study or could put the subject at risk of harm. 22. Subject does not have access to a smart phone or does not know how to use a smart phone application.
primary outcomes
primary measures
Impact of Pure Green sublingual tablets on pain due to osteoarthritis of the knee using a daily self-reported pain scale score.
Time frame: 30 days
To evaluate the safety and efficacy of Pure Green sublingual tablets for the treatment of pain due to osteoarthritis of the knee by having patients evaluate their daily pain scale score reported as 0-10 where 0 is no pain and 10 is the worst pain possible as self-reported with every dose taken by the patient in the smart phone app. The objective is to reduce the patients average daily pain scale score to less than 4.
secondary outcomes
secondary measures
Impact of Pure Green sublingual tablets on general health and well-being of Osteoarthritis of the knee patients.
Time frame: 30 Days
To evaluate the impact of Pure Green sublingual tablets on the general health and well-being of osteoarthritis of the knee patiens. The objective is to examine quality of life metrics: overall quality of life and general health, physical health, and knee pain as measured on a 1-5 scale before and after the study
Impact of Pure Green sublingual tablets on sleep improvement of patients with osteoarthritis of the knee.
Time frame: 30 Days
The Pittsburgh Sleep Quality Index will be used to compare pre and post Pure Green sublingual tablet study on sleep changes. Patients will be asked questions before beginning of the study and after completion.
Impact of Pure Green sublingual tablets on anxiety of patients with osteoarthritis if the knee
Time frame: 30 Days
The Hamilton Anxiety rating scale questionnaire will be administered before the study begins and after completion to examine the impact of Pure Green sublingual tablets on anxiety in patients with osteoarthritis of the knee. The scale of 0-4 will be used where 0 is no anxiety present and 4 is very severe anxiety.
Impact on the use of sublingual tablets as the route of administration.
Time frame: 30 Days
To explore the impact of sublingual administration on patient compliance by evaluating the number of tablets taken per day as entered by the patients into the smart phone app.
Publications
Locally readable linked articles
background referenceArthritis Research & Therapy · Free full text Snapshot provenance
- Snapshot
- 174071c0-b791-48e5-b9aa-be9475f7a4ed
- Retrieved
- 11/09/2026, 14:14:16
- SHA-256
- 4d8b23545ad9ce8dfaa65228412ec186c96d2f956f29702e09bebf0e54deac96